News and Press Releases

Acute Respiratory Distress Syndrome (ARDS)

  • Aqualung Therapeutics Appoints Two New Board Directors

    June 2022

  • Predictive Medicine, Biomarkers & the Multiple Unmet Needs in Acute Respiratory Distress Syndrome

    April 2022

  • Tucson startup looks to human trials for drug to treat lung inflammation

    March 2022

  • Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models

    Feb 2022

  • Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor

    January 2022

  • CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase

    Dec 2021

  • Dr. Joe GN Garcia speaks on the impacts of COVID-19 in the year 2020 in PharmaVOICE Magazine Nov/Dec Issue

    Nov / Dec 2021

  • Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition

    August 2021

  • Dr. Garcia Grand Rounds at Houston Methodist

    July 2021

  • CEO of Aqualung Therapeutics Corp., Joe G.N. Garcia MD, Named Invited Speaker at the First Annual Acute Respiratory Distress Syndrome Drug Development Summit

    June 2021

  • Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting

    June 2021

  • eNAMPT, an inflammation-regulatory protein is now tightly linked to COVID-19 deaths

    Feb 2021

  • Studies: eNAMPT, an inflammation-regulatory protein is now tightly linked to COVID-19 deaths

    Feb 2021

  • Healing lungs, improving data, oncology research and more

    June 2020

  • Dr. Joe GN Garcia addresses the Foe Behind Covid-19 Deaths: Acute Respiratory Distress Syndrome

    July 2020

  • Why An Experimental Therapy for Inflammatory Disorders Could Help the Fight Against COVID-19

    May 2020

  • AquaLung Therapeutics Corp. Receives NIH Approval to Advance to IND-Enabling Studies Via the STTR Fastrack Phase II Award for Development of A Novel Anti-Inflammatory Therapeutic Antibody for ARDS

    May 2020

  • Aqualung Takes Genomic Approach to COVID-19’s Killer Lung Inflammation

    April 2020

  • Deaths with COVID-19 primarily in patients transferred to ICU – KGUN9 Interview

    April 2020

  • Fight Against COVID 19 May Yield Solutions to ARDS

    April 2020

Next
Next

Chorioamnionitis